Evogene (NASDAQ:EVGN) announced a fundamental strategic refocusing alongside its fourth-quarter and full-year 2025 financial results, moving to concentrate its resources on its proprietary ChemPass AI™ tech-engine.
The shift marks a transition from a broad multi-subsidiary model to a streamlined focus on high-impact discovery for the pharmaceutical and agricultural industries.
For the fiscal year ended December 31, 2025, the Rehovot, Israel-based company reported total revenue of approximately $3.9 million.
While the company recorded an operating loss of $14 million, its net loss for the year improved to $7.8 million, aided by a $6.4 million gain from the divestment of its stake in Lavie Bio to ICL Group.
This capital-efficient strategy was further supported by a reduction in operating expenses to approximately $13.8 million, down from prior years as the company resized its workforce and discontinued non-core activities.
The core of Evogene’s 2026 outlook is the ChemPass AI™ platform, which utilizes a generative AI foundation model trained on a universe of 38 billion molecules.